Company Cytori Therapeutics Inc Deutsche Boerse AG
Equities
US23283K1051
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
||
- EUR | - |
|
Business Summary
Sales per Business
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
Pharmaceutical
100.0
%
| 0 | 100.0 % | 5 | 100.0 % | +2,093.30% |
Sales per region
USD in Million | 2022 | Weight | 2023 | Weight | Delta |
---|---|---|---|---|---|
United States
100.0
%
| 0 | 100.0 % | 5 | 100.0 % | +2,093.30% |
Managers
Managers | Title | Age | Since |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 62 | 02-09-30 |
Andrew Sims
DFI | Director of Finance/CFO | 51 | 20-02-05 |
Pius Maliakal
CTO | Chief Tech/Sci/R&D Officer | - | 23-07-26 |
Russ Havranek
PRN | Corporate Officer/Principal | - | 13-12-31 |
Members of the board
Members of the board | Title | Age | Since |
---|---|---|---|
Marc Hedrick
CEO | Chief Executive Officer | 62 | 02-09-30 |
Richard Hawkins
CHM | Chairman | 74 | 07-11-30 |
Robert Lenk
BRD | Director/Board Member | 76 | 20-02-29 |
J. Clowes
BRD | Director/Board Member | 70 | 20-02-29 |
Greg Petersen
BRD | Director/Board Member | 61 | 20-02-13 |
Director/Board Member | 64 | 19-12-31 |
Share class
Vote | Quantity | Free-Float | Company-owned shares | Total Float | |
---|---|---|---|---|---|
Stock A | 1 | 5,962,644 | 5,593,929 ( 93.82 %) | 258,425 ( 4.334 %) | 93.82 % |
Company contact information
Plus Therapeutics, Inc.
4200 Marathon Boulevard Suite 200
78756, Austin
+737 255 7194
http://www.plustherapeutics.com![address Cytori Therapeutics Inc](https://cdn.zonebourse.com/static/address/472541.png)
Sector
1st Jan change | Capi. | |
---|---|---|
+22.10% | 46.55B | |
+46.45% | 41.84B | |
-3.12% | 40.84B | |
+36.10% | 32.95B | |
-6.30% | 28.27B | |
+18.71% | 27.78B | |
+46.15% | 14.26B | |
+44.52% | 13.69B | |
+0.19% | 12.18B |
- Stock Market
- Equities
- PSTV Stock
- Stock
- Company Cytori Therapeutics Inc